ASX Announcement Sheba Medical Center Grants Approval for the EMILI 2b/3 AML Trial § Sheba Medical Center in Israel has granted site ethics approval for the pivotal EMILI Phase 2b/3 trial of RC220 in relapsed or refractory acute myeloid leukaemia (R/R AML) § Racura Board has approved the...
Sheba Grants Ethics Approval for EMILI AML Trial
Filed with ASX · · 9 pages · English
Release
In the deck
Earlier from Racura Oncology
- Racura Successfully PK Bridges RC110 RC220
- Racura Presents Bisantrene MYC Data at FCS 2026
- Letter to Shareholders, Notice of AGM & Proxy Form
- Sept 2026 Quarterly Activities Report and Appendix 4C
- HARNESS-1 First Cohort Cleared
Later from Racura Oncology
All Racura Oncology news releasesFollow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology